Liraglutide Protects Kidneys From Cisplatin Damage by Blocking Ferroptosis Iron-Death Pathway | Research

The takeaway

Liraglutide protected mouse kidneys from cisplatin-induced acute kidney injury by orchestrating ferroptosis defense mechanisms, adding renal protection to GLP-1 drug benefits.

Ferroptosis blocked
Liraglutide activated iron-death defense mechanisms to protect kidneys during cisplatin chemotherapy in mice

What the researchers found

Liraglutide protected against cisplatin-induced acute kidney injury by orchestrating ferroptosis defense, including enhanced antioxidant defenses and reduced iron accumulation.

Why it matters

Cisplatin kidney damage limits cancer treatment. If liraglutide can protect kidneys during chemotherapy, cancer patients on GLP-1 drugs for diabetes or obesity may have a built-in advantage, and liraglutide could be specifically added as a kidney protector during chemo.

The numbers in context

Specific dose and kidney function measurements were analyzed but not detailed in available abstract.

How the study worked

Mouse model of cisplatin-induced acute kidney injury treated with liraglutide. Assessed kidney function, ferroptosis markers (iron, lipid peroxidation, GPX4), antioxidant defenses, and kidney histology.

Who was studied

Mice with cisplatin-induced acute kidney injury

What this study cannot tell us

Mouse study. Cisplatin doses in mice may not match human chemotherapy protocols. The interaction between liraglutide and cisplatin anticancer efficacy needs evaluation — kidney protection must not compromise cancer treatment.

How to read the evidence

Preliminary evidence: well-designed mouse study with clear ferroptosis mechanism identification. No human chemotherapy data.

When this study was published

Published in 2025. Reveals a novel mechanism (ferroptosis defense) for GLP-1 kidney protection.

The bigger picture

GLP-1 drugs keep revealing organ-protective effects through unexpected mechanisms. Ferroptosis defense adds to the anti-inflammatory, antioxidant, and anti-apoptotic pathways already shown to mediate GLP-1 kidney protection. This multi-mechanism protection makes GLP-1 drugs increasingly important in nephrology.

Questions still open

Does liraglutide protect kidneys without reducing cisplatin anticancer efficacy?
Should cancer patients on GLP-1 drugs continue them during cisplatin chemotherapy for kidney protection?
Could liraglutide or other GLP-1 drugs become standard nephroprotectants during chemotherapy?

Common questions

What is ferroptosis?

Ferroptosis is a form of cell death caused by iron-dependent damage to cell membranes. It is different from the more familiar apoptosis. In cisplatin kidney damage, ferroptosis is a major mechanism of cell death. Liraglutide appears to block this process.

Could GLP-1 drugs protect kidneys during chemotherapy?

This mouse study suggests yes — liraglutide protected kidneys from cisplatin damage by blocking ferroptosis. Cancer patients already taking GLP-1 drugs may have some built-in kidney protection, but clinical studies are needed to confirm this and ensure it does not affect cancer treatment.

Read the original research

Liraglutide orchestrates ferroptosis defense against murine cisplatin acute kidney injury: NRF2 activation via both KEAP1-dependent and -independent mechanisms is essential for SLC7A11/GPX4 renoprotection.

Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS), 92, 127755

View on PubMed ↗Publisher’s paper ↗

Citation

Abdel Razek, Nermeen S; Nassar, Noha N; Sayed, Rabab H; El-Sahar, Ayman E; Abdallah, Dalaal M. (2025). Liraglutide orchestrates ferroptosis defense against murine cisplatin acute kidney injury: NRF2 activation via both KEAP1-dependent and -independent mechanisms is essential for SLC7A11/GPX4 renoprotection.. Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS), 92, 127755. https://doi.org/10.1016/j.jtemb.2025.127755